Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Pfizer Inc. (PFE), United Therapeutics Corporation (UTHR): How Big Is Organovo Holdings Inc (ONVO)’s Market Opportunity?

Organovo Holdings Inc (NYSEMKT:ONVO) is a little company that people think could do big things. Foremost among those “things” is the 3-D printing of human organs for transplants.

But the problem with such grandiose potential is that it can often distract investors from the more tangible opportunities lying in plain sight. As you’ll see, Organovo Holdings Inc (NYSEMKT:ONVO) could have much more practical streams of revenue sooner than printed organs ever come along.

A market in dire need of new efficiencies

In 2010, the pharmaceutical industry spent $50 billion on research and development of new treatments. At the same time, the FDA approved only 20 new drugs.

Sources: Organovo, FDA, Pharmaceutical Research Manufacturers of America.

Though much of the money invested is for the drugs of the future (well beyond 2010), these numbers represent just how expensive it is to bring a drug to market.

More representative figures do exist to put the spending in perspective: A new drug, on average, takes 12 years and $1.2 billion to bring to market. And that doesn’t even take into consideration all of the drugs that never see the inside of a pharmacy.

Sometimes, drug companies believe they have a big hit on their hands because of successful tests in the lab with two-dimensional cells, or on animal subjects. It isn’t until human trials begin — and after hundreds of millions of dollars have been spent — that unexpected toxicities arise.

These toxicities either set the drug back significantly or force companies to scrap their plans altogether. BioWorld Today estimates that “[f]orty percent of drug development costs go toward molecules that ultimately fail,” often because of “unforeseen toxicities.” With the industry spending $50 billion per year, that means $20 billion down the drain.

Primary application = killing drugs faster

Clearly, any company that can add reliable and cost-cutting efficiencies to the process could be richly rewarded. And it is here where Organovo Holdings Inc (NYSEMKT:ONVO)’s most practical revenue stream could materialize.

Organovo Holdings Inc (NYSEMKT:ONVO) enters the scene by offering pharmaceutical companies three-dimensional tissues that mimic native human biology — and aim to have a much higher predictive value for the success of drugs than prior methods.

Already, the company has partnered with both Pfizer Inc. (NYSE:PFE) and United Therapeutics Corporation (NASDAQ:UTHR) to research and test out the 3-D tissues. The collaboration with Pfizer Inc. (NYSE:PFE) ended last year, and Organovo Holdings Inc (NYSEMKT:ONVO) is waiting to hear back to see if Pfizer Inc. (NYSE:PFE) wants to continue collaborating. The United Therapeutics Corporation (NASDAQ:UTHR) deal is still ongoing and was expanded upon in 2012.

More long term, market research firm Scientia Advisors sees a specific market opportunity of more than $500 million for Organovo Holdings Inc (NYSEMKT:ONVO) by 2018. Currently, the company has functional liver tissues developed, but it hopes to expand to kidney and heart cells.

Organovo would earn its keep by manufacturing the cells and providing them to the drug companies. Along the way, it hopes to continue partnering with drug companies and academic institutions to expand the number of organ cells it offers. Specifically, Organovo is looking for collaboration deals worth between $10 million and $30 million, where the company could have a 3% to 7% royalty.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.